权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Elucidating and Targeting tumor dependencies and drug resistance determinants at the single cell level

在单细胞水平上阐明和靶向肿瘤依赖性和耐药性决定因素

基本信息

批准号：
10505333
负责人：
ANDREA CALIFANO
金额：
$ 99.12万
依托单位：
COLUMBIA UNIVERSITY HEALTH SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-21 至 2027-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10505333
关键词：
Acute Address Adult Biological Assay Biological Markers Breast Adenocarcinoma CLIA certified Cancer Patient Categories Cells Clinical Clinical Trials Collaborations Combined Modality Therapy Data Set Dependence Desmoplastic Small Round Cell Tumor Development Dissection Drug Targeting Drug resistance Genetic Genetic Transcription Glioblastoma Goals Health Immunotherapy Individual Maintenance Malignant Childhood Neoplasm Malignant Neoplasms Malignant neoplasm of prostate Mediating Methodology Molecular Mutate Mutation Network-based Neuroblastoma Neuroendocrine Tumors Oncogenes Oncoproteins Pathway interactions Patients Pediatric Neoplasm Pharmaceutical Preparations Pharmacology Population Progression-Free Survivals Prostate Prostate Adenocarcinoma Proteins Relapse Reporter Genes Research Personnel Reverse engineering Role Signal Transduction Slice Testing The Cancer Genome Atlas Tissues Tumor Subtype Validation base biomarker development cancer cell cancer genetics cancer pharmacology cohort design drug sensitivity falls follow-up improved neoplastic cell novel patient derived xenograft model resistance mechanism response sarcoma single-cell RNA sequencing success targeted treatment therapeutic target therapeutically effective transcription factor tumor tumorigenesis

项目摘要

Cancer targets fall into two major categories: oncoproteins that elicit tumor essentiality due to their direct role in tumorigenesis or tumor maintenance (oncogene dependencies) and proteins that elicit synthetic lethality with oncogene mutations but are not themselves mutated (non-oncogene dependencies). Unfortunately, clonal selection and inherent cancer cell plasticity—as well as the ability of cancer cells to undergo adaptation and reprogramming to drug resistant states, following treatment—are currently challenging the concept of individual proteins as effective therapeutic targets for an entire tumor mass—especially if identified from bulk tissue analyses. Indeed, despite several successes, only 5% – 11% of cancer patients benefit from targeted therapy, based on progression free survival, often with no substantial overall survival differences; while promising, immune therapy is also subject to selective response and relapse. To address these challenges, our proposal will study a more universal class of mutation-agnostic, non-oncogene dependencies implemented by tightly-autoregulated sets of Master Regulator (MR) proteins that we have called Tumor Checkpoint (TC) modules. We have shown that MR proteins mechanistically implement a tumor cell’s transcriptional state by canalizing the effect of mutations and aberrant signals in their upstream pathways. As such, within the context of a transcriptionally-distinct tumor subtype, they represent largely mutation-agnostic dependencies. Our proposal will thus focus on the elucidation and pharmacological targeting of MRs and TC-modules at the single cell level, within molecularly distinct, yet co-existing tumor subpopulations. This will lead to design of successful combination therapy approaches and will help elucidate and pharmacologically target mechanisms of drug resistance and cell adaptation. To accomplish these goals, we will extend a highly successful, network- based framework developed by our CTD2 Center, for the elucidation, validation, and pharmacological targeting of MR proteins and TC-modules. Indeed, we have shown that genetic or pharmacological targeting of this new class of tumor dependencies can induce collapse of TC-module activity and induce loss of tumor viability in a wide range of malignancies, ranging from glioblastoma, neuroblastoma, and neuroendocrine tumors, to prostate and breast adenocarcinoma, among many others. In particular, analysis of 25 TCGA cohorts has identified 112 transcriptionally distinct tumor subtypes, each one regulated by a distinct subtype-specific TC-module, which was independent of patient-specific mutations. These methodologies are especially relevant in rare, aggressive tumors—including several pediatric malignancies—where cohort size may be too small to support correlative analyses. Critically, these studies have led to the development of two NY/CA Dpt. of Health approved, CLIA- compliant tests, OncoTarget and OncoTreat, whose predictions have spurred several clinical trials. These approaches will be extended to elucidate TC-module dependencies and to develop drug sensitivity biomarkers at the single cell level.

癌症靶点主要分为两大类：一类是癌蛋白，由于其在肿瘤中的直接作用而引发肿瘤的必要性